Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc-Matthieu Fornecker

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Blood Advances|August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapyVincent Camus, Roch Houot, Gabriel Brisou, et al.
Oncotarget|July 27, 2016
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyEmilie Reboursiere, Fabien Le Bras, Charles Herbaux, et al.
Bone Marrow Transplantation|January 14, 2018
Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular TherapyJordan Gauthier, Xavier Poiré, Anne-Claire Gac, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Hemasphere|May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA groupPierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Blood Advances|August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapyVincent Camus, Roch Houot, Gabriel Brisou, et al.
Oncotarget|July 27, 2016
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyEmilie Reboursiere, Fabien Le Bras, Charles Herbaux, et al.
Bone Marrow Transplantation|January 14, 2018
Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular TherapyJordan Gauthier, Xavier Poiré, Anne-Claire Gac, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Hemasphere|May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA groupPierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Pageof 8